Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the completion of a series of three clinical studies investigating the safety and efficacy of a serum, eye cream and moisturizer, each containing the Company’s SmartPeptides™ technology, including the newly developed Heptapeptide-7. These studies demonstrate improvement in skin texture and appearance as well as the decrease in fine lines and wrinkles with Striking™ Skin Care formulations.
“Our SmartPeptides technology found in Striking Skin Care products performed well in clinical evaluation with high consumer appeal,” said Dr. Tim Falla, Chief Scientific Officer at Helix BioMedix. “We are delighted with the results of these third-party studies documenting the benefits of SmartPeptides technology for people seeking improved skin texture and hydration. We plan to present the studies at upcoming dermatology conferences, while we wait for publication of the complete study.”